



truscreen
a world without
cervical cancer

NZX/ASX Announcement

10 August 2022

China Distributor Relaunches TruScreen devices in Xinjiang Uygur Autonomous Region

Key Highlights

- TruScreen distributor Beijing Siweixiangtai Tech Co Ltd (SWXT) has relaunched distribution for the Xinjiang Uygur Autonomous Region (UAR)
- Project was previously put on hold and further delayed by COVID
- Xinjiang Regional price approval for the TruScreen device was previously approved for Xinjiang UAR in 2020
- Xinjiang UAR in China's far north-west has 26 million people over a vast area of 1.7m Km²
- Initial order of 20 TruScreen (China assembled) cervical cancer screening devices and 12,960 SUS has been delivered

TruScreen Group Limited (NZX/ASX: TRU) ('TruScreen' or 'the Company') is pleased to announce that its China distributor Beijing Siweixiangtai Technology Company Ltd (SWXT) has relaunched distribution of TruScreen cervical cancer screening device to Xinjiang Uygur Autonomous Region.

With easing of COVID restrictions, the relaunch of distribution in Xinjiang UAR resumes the policy focus of China's Central and Provincial governments to continue with their national cervical cancer screening programmes to achieve the World Health Organisation's strategic screening targets by 2030 and of eliminating cervical cancer by the end of the century.

The Xinjiang UAR has a population of 26 million spread over an area of 1.7 million Km². This vast area has many ethnic minority groups in remote locations with the Xinjiang UAR government providing special funding for cancer screening programmes.

The TruScreen cervical cancer screening device is ideally suited for Xinjiang UAR and has significant advantages in undertaking cervical cancer screening programmes in this vast area with many remote locations. The ability to provide a **real time** result with a robust TruScreen cervical cancer screening device, without the need for laboratory infrastructure, will support the UAR government's programme of improving the lives of women in ethnic minorities.

In addition to the 912 hospitals in Xinjiang UAR, there are 16,588 community medical centres, a key target market for use of the TruScreen device.

TruScreen has recently delivered from its China based manufacturing facility, 20 TruScreen cervical cancer screening devices, and 12,960 SUS to commence this programme.

TruScreen CEO Juliet Hull said: *"with a population of over 1.4 billion people, China remains the most established and significant market for TruScreen. The strategic decision to establish a manufacturing, together with service and recalibration facilities in China, is providing our distributor with the competitive advantage to expand their market reach within the country, with a locally manufactured device".*

This announcement has been approved by the Board.

-ENDS-

For more information, visit www.truscreen.com or contact:

Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au
+61 2 8999 3699

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening technologies that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.

TruScreen's cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.

The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical cancer screening programmes and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.

To learn more, please visit: www.truscreen.com/